RCS - Redx Pharma Limited - US FDA lifts Partial Clinical Hold on Zelasudil

FTI Consulting

07/01/2026 07:00

RNS Number : 8981N

Redx Pharma Limited

07 January 2026

 

 

 

REDX PHARMA LIMITED

("Redx" or the "Company")

US FDA lifts Partial Clinical Hold on Zelasudil

 

Alderley Park, UK, 7 January 2026 Redx Pharma Ltd, the clinical-stage, biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease announces that the Partial Clinical Hold (PCH) placed on the zelasudil (RXC007) Phase 2a trial in Idiopathic Pulmonary Fibrosis (IPF) by the Division of Pulmonology, Allergy, and Critical Care (DPACC) of the US Food and Drug Administration (FDA) has been lifted.

The PCH was issued as a result of a non-clinical observation and limited the dosing period to 28-days in the US during the initial Phase 2a study. Following the submission of the final 12-week data, and additional 12-week open label extension (OLE) data from the completed Phase 2a study (RXC007 / 0002) undertaken at 31 sites across Europe and the UK, the FDA have lifted the PCH resulting in an open IND in the US to support the further clinical development of zelasudil. 

Lisa Anson, CEO, Redx Pharma, commented: "We are thrilled with the decision of the FDA to lift the partial clinical hold placed on zelasudil following the review of our clinical data package. This will allow the next stage of clinical development for zelasudil to take place on a global scale. In addition to our signal in IPF patients, our pre-clinical work has shown zelasudil to have utility across a number of fibrotic diseases and we are focused on bringing this exciting new therapeutic treatment option to patients."

The Phase 2a study aimed to assess safety, tolerability, pharmacokinetic and initial efficacy in patients with IPF. The Phase 2a data showed zelasudil to be well-tolerated with evidence of anti-fibrotic activity supported by circulating biomarkers and a numerical improvement in Forced Vital Capacity (FVC) decline in patients with IPF vs placebo. The pharmacokinetic data matched predictions from Phase 1 healthy volunteer studies and combinability with standard of care agents was demonstrated, with no clinically relevant drug-drug interactions seen with either nintedanib or pirfenidone.

The full Phase 2a data set was presented at the European Respiratory Society (ERS) meeting in Amsterdam in September 2025 and is available on the Company website at: https://www.redxpharma.com/scientific-publications/

The encouraging clinical data supports further investigation of zelasudil as a potential treatment for IPF and other interstitial lung diseases and Redx is seeking a partner to support the next stages of clinical development.

About Zelasudil (RXC007)

Zelasudil is a potential best-in-class potent, highly selective and orally-active inhibitor that targets Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in cell signalling pathways, central to fibrosis. Redx are developing zelasudil as a potential treatment for IPF and other interstitial lung diseases, as well as other conditions including Metabolic dysfunction-associated steatohepatitis (MASH) and cancer-associated fibrosis, where the Company has generated supportive pre-clinical data.

 

For further information, please contact:
Redx Pharma Limited
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com
T: +44 (0)1625 469 918
FTI Consulting
T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin


 

 

About Redx Pharma Limited

 

Redx Pharma is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicine for the treatment of fibrotic disease. Pioneering the next generation of anti-fibrotic medicines, the Company is currently progressing RXC008, a first-in-class GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease through the clinic and has completed a Phase 2a program in idiopathic pulmonary fibrosis (IPF) with zelasudil, a potential best-in-class selective ROCK2 inhibitor.

 

Additionally, the Company has an early-stage discoidin domain receptor (DDR) inhibitor program with potential to be a first-in-class approach for chronic kidney disease. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage assets and discovery pipeline, but also by its strategic transactions including with AstraZeneca and Jazz Pharmaceuticals, as well as the sale of pirtobrutinib (RXC005, LOXO-305) to Loxo Oncology (Eli Lilly). Pirtobrutinib, the only approved non-covalent or reversible Bruton's tyrosine kinase (BTK) inhibitor, has transitioned quickly from FDA approval in the US, to broader international approvals. 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAEAEFKESXKEAA